A study of NIAGEN in patients with mitochondrial myopathy
Latest Information Update: 19 Jan 2023
Price :
$35 *
At a glance
- Drugs Nicotinamide riboside (Primary)
- Indications Mitochondrial myopathies
- Focus Pharmacodynamics
- 17 Jan 2023 Results published in a ChromaDex media release.
- 17 Jan 2023 According to a ChromaDex media release, 44% of the study participants were female, and 56% were male. The study also included a small group of BMI-concordant (same amount of body fat and muscle) identical twin pairs (n=8, 4 twin pairs).
- 17 Jan 2023 According to a ChromaDex media release, the trial is a part of the ChromaDex External Research Program (CERP™).